IN2012DN02485A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02485A IN2012DN02485A IN2485DEN2012A IN2012DN02485A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A IN 2485DEN2012 A IN2485DEN2012 A IN 2485DEN2012A IN 2012DN02485 A IN2012DN02485 A IN 2012DN02485A
- Authority
- IN
- India
- Prior art keywords
- rheumatoid arthritis
- methods
- therapeutic agents
- identifying
- diagnosing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27594809P | 2009-09-03 | 2009-09-03 | |
US25242409P | 2009-10-16 | 2009-10-16 | |
PCT/US2010/047734 WO2011028945A1 (en) | 2009-09-03 | 2010-09-02 | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02485A true IN2012DN02485A (en) | 2015-08-28 |
Family
ID=43625246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2485DEN2012 IN2012DN02485A (en) | 2009-09-03 | 2010-09-02 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8728730B2 (en) |
EP (2) | EP2473637B1 (en) |
JP (3) | JP5996429B2 (en) |
KR (1) | KR20120104517A (en) |
CN (2) | CN107385034B (en) |
BR (1) | BR112012004777A2 (en) |
CA (1) | CA2772929A1 (en) |
HK (1) | HK1245341A1 (en) |
IN (1) | IN2012DN02485A (en) |
MX (2) | MX2012002766A (en) |
RU (2) | RU2539112C2 (en) |
WO (1) | WO2011028945A1 (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
US8645166B2 (en) | 2007-07-16 | 2014-02-04 | Russell W. Bessette | System and method for scoring illness complexity to predict healthcare cost |
TW201438738A (en) | 2008-09-16 | 2014-10-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
CN107385034B (en) | 2009-09-03 | 2021-08-17 | 弗·哈夫曼-拉罗切有限公司 | Methods for treating, diagnosing and monitoring rheumatoid arthritis |
US8846397B2 (en) | 2010-01-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments |
US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
JP2013520476A (en) | 2010-02-26 | 2013-06-06 | ノヴォ ノルディスク アー/エス | Stable antibody-containing composition |
EP4234698A3 (en) | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
KR20130066631A (en) | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
KR101993921B1 (en) | 2010-12-06 | 2019-06-28 | 시애틀 지네틱스, 인크. | Humanized antibodies to liv-1 and use of same to treat cancer |
JP5885926B2 (en) * | 2011-01-28 | 2016-03-16 | シスメックス株式会社 | Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the method |
KR20140022815A (en) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | Biological markers and methods for predicting response to b-cell antagonists |
WO2013067355A1 (en) | 2011-11-04 | 2013-05-10 | Novartis Ag | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
WO2013117751A2 (en) | 2012-02-10 | 2013-08-15 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
WO2013135789A1 (en) * | 2012-03-15 | 2013-09-19 | Universiteit Hasselt | Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients |
WO2013164440A1 (en) | 2012-05-03 | 2013-11-07 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
WO2014028374A1 (en) * | 2012-08-17 | 2014-02-20 | Eli Lilly And Company | Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-baff antibody therapy |
WO2014118550A1 (en) * | 2013-01-31 | 2014-08-07 | The University Of Birmingham | Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation |
EP2813850A1 (en) * | 2013-06-10 | 2014-12-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting rheumatoid arthritis treatment response |
US20160274106A1 (en) * | 2013-06-21 | 2016-09-22 | Catholic University Industry-Academic Cooperation Foundation | Biomarker for rheumatoid arthritis diagnosis or activity evaluation |
AR096687A1 (en) | 2013-06-24 | 2016-01-27 | Genentech Inc | ANTI-FCRH5 ANTIBODIES |
CN103399147B (en) * | 2013-08-07 | 2015-06-17 | 苏州大学 | Polygalacturonic acid novel application |
KR101628035B1 (en) * | 2013-09-13 | 2016-06-09 | 인제대학교 산학협력단 | Method for screening therapeutic agents of ovarian cancer using VSIG4 |
CN103513040B (en) * | 2013-10-16 | 2015-03-11 | 常晓天 | Application of protein CD38 to preparation of rheumatoid arthritis diagnosing marker |
EP2863231A1 (en) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter |
ES2824108T3 (en) | 2014-03-12 | 2021-05-11 | Icahn School Med Mount Sinai | Method to identify kidney allograft recipients at risk for chronic injury |
RU2554755C1 (en) * | 2014-05-26 | 2015-06-27 | Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) | Diagnostic technique for rheumatoid arthritis |
ES2850281T3 (en) | 2014-06-26 | 2021-08-26 | Icahn School Med Mount Sinai | Method for diagnosing acute subclinical and clinical rejection by analyzing predictive gene sets, a therapeutic agent for use in treatment, and kits to determine expression |
KR20160048442A (en) * | 2014-10-24 | 2016-05-04 | 가톨릭대학교 산학협력단 | Biomarkers related to rheumatoid arthritis |
WO2016120387A1 (en) * | 2015-01-29 | 2016-08-04 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
CN105988009B (en) * | 2015-02-28 | 2018-03-13 | 复旦大学附属华山医院 | Purposes of the Netrin 4 in the preparation of detection stomach cancer and prognostic marker is prepared |
WO2016154553A1 (en) * | 2015-03-25 | 2016-09-29 | La Jolla Institute For Allergy And Immunology | Cxcl13 as an indicator of germinal center activity and immune response |
WO2016183310A1 (en) * | 2015-05-12 | 2016-11-17 | Steere Allen C | Autoantigens for diagnosis of rheumatoid arthritis |
CR20180031A (en) * | 2015-06-16 | 2018-05-07 | Genentech Inc | ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FCRH5 AND METHODS FOR USE |
CN105200159B (en) * | 2015-11-06 | 2018-06-15 | 北京致成生物医学科技有限公司 | Osteoarthritis diagnosis and treatment reagent and its application |
GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
US11644473B2 (en) * | 2016-04-15 | 2023-05-09 | Rowan University | Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients |
US20170321286A1 (en) * | 2016-05-05 | 2017-11-09 | Exact Sciences Corporation | Detection of lung neoplasia by amplification of rna sequences |
EP3463441B1 (en) | 2016-06-07 | 2023-10-25 | The General Hospital Corporation | Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis |
RU2622597C1 (en) * | 2016-07-05 | 2017-06-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Method for joint pain syndrome prediction for patients with signs of connective tissue dysplasia |
GB201616557D0 (en) * | 2016-09-29 | 2016-11-16 | Secretary Of State For Health The | Assay for distinguishing between sepsis and systemic inflammatory response syndrome |
CN106526196B (en) * | 2016-10-08 | 2018-08-10 | 北京大学人民医院 | Applications of the SR-A as Diagnosis of Rheumatoid Arthritis marker and intervention target spot |
CN110036023B (en) * | 2016-11-09 | 2023-01-10 | Icm株式会社 | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient |
EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
KR102588627B1 (en) | 2017-03-08 | 2023-10-16 | 김성진 | Composition for preparing extracellular matrix using MAST4 gene and method for preparing the same |
WO2018164507A2 (en) * | 2017-03-08 | 2018-09-13 | 주식회사 길로 | Extracellular matrix-producing composition using mast4 gene and preparation method therefor |
US11325969B2 (en) * | 2017-08-29 | 2022-05-10 | Veritas Therapeutics Inc. | FGL2 antibodies and binding fragments thereof and uses thereof |
AU2018327221A1 (en) * | 2017-11-13 | 2019-05-30 | The Multiple Myeloma Research Foundation, Inc. | Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database |
EP3728638A1 (en) * | 2018-01-24 | 2020-10-28 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra) |
CN108359726B (en) * | 2018-02-28 | 2020-09-04 | 固安博健生物技术有限公司 | Application of CORO2B as molecular diagnosis and treatment marker |
WO2019178546A1 (en) | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
AU2019255206A1 (en) | 2018-04-16 | 2020-11-12 | Icahn School Of Medicine At Mount Sinai | Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
US20190359985A1 (en) * | 2018-05-22 | 2019-11-28 | John Lawrence Mee | Adjustable method for sustainable human cognitive enhancement |
CN109142729B (en) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | Lung cancer marker anti-HMGB 3 autoantibody and application thereof |
US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
US10723191B1 (en) | 2018-07-01 | 2020-07-28 | Softwheel Ltd. | In-wheel three-arm suspension for vehicles |
CN110917351A (en) * | 2018-09-20 | 2020-03-27 | 华中科技大学同济医学院附属同济医院 | Use of MBD2 inhibitors for the prevention and treatment of fibrotic diseases |
US20210382050A1 (en) * | 2018-10-19 | 2021-12-09 | The Regents Of The University Of Michigan | Method for monitoring autoimmune disease |
CN109207584A (en) * | 2018-11-01 | 2019-01-15 | 固安博健生物技术有限公司 | Application of the MARCO as the molecular marker of early diagnosis osteoarthritis |
EP3921335A4 (en) * | 2019-02-08 | 2023-02-08 | The Regents Of The University Of California | Compositions and methods involving layilin |
CA3139508A1 (en) | 2019-05-08 | 2020-11-12 | Janssen Biotech, Inc. | Materials and methods for modulating t cell mediated immunity |
CA3145237A1 (en) | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
CN114573663B (en) * | 2019-08-27 | 2023-08-11 | 广东菲鹏生物有限公司 | Citrulline peptide and application thereof, and detection reagent and kit for rheumatoid arthritis |
CN110408590B (en) * | 2019-09-06 | 2022-10-25 | 遵义医学院附属医院 | Method for inducing differentiation of human mesenchymal stem cells into osteoblasts and application thereof |
GB201914079D0 (en) * | 2019-09-30 | 2019-11-13 | Univ London Queen Mary | Method of predicting requirement for biologic therapy |
KR102596937B1 (en) * | 2019-11-07 | 2023-11-03 | 가톨릭대학교 산학협력단 | Biomarker for diagnosing pannus of rheumatoid arthritis and use thereof |
CN111091909B (en) * | 2019-11-26 | 2022-05-31 | 中国信息通信研究院 | Medical image identification method and device |
CN113122628B (en) * | 2019-12-30 | 2023-08-11 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | Application of CLEC5A gene as marker in diagnosis and treatment of endometrial cancer |
CN112114126B (en) * | 2020-08-13 | 2023-03-24 | 川北医学院 | Diagnostic marker for systemic lupus erythematosus and application thereof |
EP4217508A1 (en) * | 2020-09-22 | 2023-08-02 | The Secretary Of State For Defence | Apparatus, kits and methods for predicting the development of sepsis |
CN112646887B (en) * | 2020-12-23 | 2023-02-28 | 广州医科大学附属第五医院 | ZNF239 as target for diagnosis and treatment of liver cancer |
CN112946269B (en) * | 2020-12-29 | 2022-12-27 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Application of ABCA1 and CD68 as prognosis markers in preparation of liver cancer prognosis prediction kit |
CN113186281B (en) * | 2021-04-02 | 2023-02-28 | 广州医科大学附属第五医院 | INAVA as a marker for hepatocellular carcinoma |
CN113512582A (en) * | 2021-04-15 | 2021-10-19 | 上海鸿准生物医药科技有限公司 | Application of SLC22A18 in allergic and inflammatory diseases |
CN113307835B (en) * | 2021-04-21 | 2022-12-13 | 南通大学 | siRNA and application thereof in preparation of chronic pain treatment medicine |
WO2022264134A1 (en) * | 2021-06-13 | 2022-12-22 | Technion Research & Development Foundation Limited | Method for determining suitability to anti-tnf alpha therapy |
WO2023158713A1 (en) * | 2022-02-16 | 2023-08-24 | Ampel Biosolutions, Llc | Unsupervised machine learning methods |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434227A (en) * | 1982-02-08 | 1984-02-28 | Abbott Laboratories | Immunoassay for class specific immunoglobulin antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CA1261257A (en) | 1984-09-19 | 1989-09-26 | Helgi Valdimarsson | Prognostic value of rheumatoid factor isotypes and their association with disease activity |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
JPH10513355A (en) | 1995-02-08 | 1998-12-22 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | Human chemokine β-11 and human chemokine α-1 |
US6139832A (en) * | 1995-02-08 | 2000-10-31 | Human Genome Sciences, Inc. | Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2222280A1 (en) | 1995-06-05 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
DE69729283T2 (en) | 1996-03-20 | 2005-05-25 | Immunomedics, Inc. | GLYCOSYLATED IgG ANTIBODIES |
KR20050004269A (en) | 1996-10-25 | 2005-01-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Neutrokine alpha |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
WO1998027114A2 (en) | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
CA2303424A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | Kay - a novel immune system protein |
DE69837678T2 (en) * | 1997-10-29 | 2007-12-27 | Otsuka Pharmaceutical Co., Ltd. | COMPOSITION FOR INHIBITING THE PROLIFERATION OF SMOOTH MUSCULATURE AND METHOD FOR THE DIAGNOSIS OF ARTERIOSCLEROSIS |
US6110695A (en) * | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
PT1068241E (en) | 1998-04-02 | 2007-11-19 | Genentech Inc | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2329254T3 (en) | 1999-01-07 | 2009-11-24 | Zymogenetics, Inc. | THERAPEUTIC USES OF BR43X2 SOLUBLE RECEIVERS. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60042785D1 (en) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | IMMUNOTHERAPY OF AUTOIMMUNE DISEASES THROUGH THE USE OF B-CELL SPECIFIC ANTIBODIES |
BRPI0013391B8 (en) | 1999-08-17 | 2021-05-25 | Apotech R&D S A | use of bcma polypeptides in the preparation of a pharmaceutical composition to treat an autoimmune disease or a b-cell lymphoproliferative disorder |
DE10041402A1 (en) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Novel compounds that inhibit factor Xa activity |
ATE296668T1 (en) * | 1999-09-01 | 2005-06-15 | Boehringer Ingelheim Pharma | COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES CONTAINING AGENTS THAT INHIBIT ICAM-1/LFA-1 INTERACTIONS AND AGENTS THAT INHIBIT CD40-CD40 LIGAND INTERACTIONS |
US7105149B1 (en) * | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
WO2001087979A2 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
EP1674477B1 (en) | 2000-08-18 | 2009-12-09 | Dyax Corp. | Binding polypeptides for B lymphocyte stimulator protein (BLYS) |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
ES2329012T3 (en) | 2000-11-07 | 2009-11-20 | Zymogenetics, Inc. | RECEIVER OF THE HUMAN TUMOR NECROSIS FACTOR. |
EP2301971A1 (en) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
US6818406B2 (en) * | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
PT1385882E (en) | 2001-05-11 | 2008-01-11 | Amgen Inc | Peptides and related molecules that bind to tall-1 |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
JP2005510208A (en) | 2001-08-03 | 2005-04-21 | ジェネンテック・インコーポレーテッド | TACIs and BR3 polypeptides and uses thereof |
AU2002330074A1 (en) | 2001-09-21 | 2003-04-01 | Amgen Inc. | Tall-1 receptor molecules and uses thereof |
US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
US20050202421A1 (en) * | 2001-10-31 | 2005-09-15 | Raphael Hirsch | Method for diagnosis and treatment of rheumatoid arthritis |
US20030224386A1 (en) * | 2001-12-19 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis |
CN101914158A (en) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
DE60334364D1 (en) | 2002-02-21 | 2010-11-11 | Univ California | TREATMENT PROCEDURE USING ANTI-CD22 ANTIBODIES |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
WO2004009479A1 (en) | 2002-07-18 | 2004-01-29 | Fabio Perini S.P.A. | Storage unit for elongated products |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
KR20100050587A (en) | 2002-10-17 | 2010-05-13 | 젠맵 에이/에스 | Human monoclonal antibodies against cd20 |
JP4351674B2 (en) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants and their use and use |
SE0300959D0 (en) | 2002-12-19 | 2003-04-02 | Pharmacia Ab | Methods for predicting therapeutic response to agents acting on the growth hormone receptor |
US6962006B2 (en) | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
PT1631313E (en) * | 2003-06-05 | 2015-07-02 | Genentech Inc | Combination therapy for b cell disorders |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
WO2005029091A2 (en) * | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
DE102004016437A1 (en) * | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Method for detecting signatures in complex gene expression profiles |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
BRPI0510885A (en) * | 2004-06-04 | 2007-12-26 | Genentech Inc | lupus treatment method and industrialized article |
WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
SG165344A1 (en) | 2004-10-05 | 2010-10-28 | Genentech Inc | Method for treating vasculitis |
AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
JP2009502936A (en) * | 2005-07-25 | 2009-01-29 | トルビオン ファーマシューティカルズ, インコーポレイテッド | Single dose of CD20 specific binding molecule |
KR20080056714A (en) | 2005-08-09 | 2008-06-23 | 지모제넥틱스, 인코포레이티드 | Methods for treating b-cell malignancies using taci-ig fusion molecule |
CA2624359A1 (en) * | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
US20090128815A1 (en) | 2006-03-15 | 2009-05-21 | Koninklijke Philips Electronics N.V. | Remote control pointing technology with roll detection |
GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
CA2646902C (en) | 2006-04-21 | 2017-01-31 | Centocor Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
US20080227655A1 (en) * | 2006-05-16 | 2008-09-18 | Michael Bevilacqua | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
US20070269827A1 (en) * | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
WO2008156494A1 (en) * | 2006-11-03 | 2008-12-24 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders |
EP2084298A1 (en) | 2006-11-09 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
EP2132343B1 (en) | 2007-03-01 | 2012-08-29 | Université Catholique de Louvain | Method for the determination and the classification of rheumatic conditions |
CA2682666A1 (en) | 2007-03-30 | 2008-10-09 | Centocor Ortho Biotech Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
EP2137325A1 (en) * | 2007-04-02 | 2009-12-30 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
JP5719591B2 (en) | 2007-06-08 | 2015-05-20 | バイオジェン アイデック エムエー インコーポレイティドBiogen Idec Inc. | Biomarker for predicting anti-TNF responsiveness or non-responsiveness |
US20100261881A1 (en) * | 2007-09-03 | 2010-10-14 | Protagen Ag | Marker sequences for rheumatoid arthritis and use thereof |
WO2009102366A2 (en) * | 2007-11-19 | 2009-08-20 | Wyeth | Expression of orphan gpr64 in inflammatory diseases |
US8121883B2 (en) * | 2008-02-07 | 2012-02-21 | International Business Machines Corporation | Method and system for automatically prioritizing opportunity based customer requirements |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
CN107385034B (en) | 2009-09-03 | 2021-08-17 | 弗·哈夫曼-拉罗切有限公司 | Methods for treating, diagnosing and monitoring rheumatoid arthritis |
-
2010
- 2010-09-02 CN CN201710584303.6A patent/CN107385034B/en active Active
- 2010-09-02 KR KR1020127008453A patent/KR20120104517A/en not_active Application Discontinuation
- 2010-09-02 IN IN2485DEN2012 patent/IN2012DN02485A/en unknown
- 2010-09-02 MX MX2012002766A patent/MX2012002766A/en active IP Right Grant
- 2010-09-02 EP EP10814522.8A patent/EP2473637B1/en active Active
- 2010-09-02 WO PCT/US2010/047734 patent/WO2011028945A1/en active Application Filing
- 2010-09-02 BR BR112012004777A patent/BR112012004777A2/en not_active IP Right Cessation
- 2010-09-02 US US12/874,972 patent/US8728730B2/en active Active
- 2010-09-02 RU RU2012112822/10A patent/RU2539112C2/en not_active IP Right Cessation
- 2010-09-02 EP EP16203656.0A patent/EP3211094A3/en not_active Withdrawn
- 2010-09-02 CN CN201080049387.XA patent/CN102597268B/en active Active
- 2010-09-02 CA CA2772929A patent/CA2772929A1/en not_active Abandoned
- 2010-09-02 JP JP2012528063A patent/JP5996429B2/en active Active
- 2010-09-02 MX MX2014012257A patent/MX353186B/en unknown
-
2014
- 2014-04-08 US US14/248,135 patent/US9822400B2/en active Active
- 2014-11-06 RU RU2014145058A patent/RU2014145058A/en not_active Application Discontinuation
-
2016
- 2016-06-23 JP JP2016124696A patent/JP6895718B2/en active Active
-
2018
- 2018-04-03 HK HK18104432.8A patent/HK1245341A1/en unknown
-
2020
- 2020-09-23 JP JP2020158134A patent/JP2021019594A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013503643A (en) | 2013-02-04 |
MX353186B (en) | 2018-01-05 |
US9822400B2 (en) | 2017-11-21 |
EP2473637A1 (en) | 2012-07-11 |
RU2539112C2 (en) | 2015-01-10 |
CN107385034A (en) | 2017-11-24 |
MX2012002766A (en) | 2012-04-02 |
EP3211094A3 (en) | 2017-11-01 |
HK1245341A1 (en) | 2018-08-24 |
JP5996429B2 (en) | 2016-09-21 |
JP6895718B2 (en) | 2021-06-30 |
US8728730B2 (en) | 2014-05-20 |
WO2011028945A1 (en) | 2011-03-10 |
KR20120104517A (en) | 2012-09-21 |
EP2473637B1 (en) | 2017-03-29 |
RU2014145058A (en) | 2016-05-27 |
EP3211094A2 (en) | 2017-08-30 |
RU2012112822A (en) | 2013-10-10 |
US20140341887A1 (en) | 2014-11-20 |
CA2772929A1 (en) | 2011-03-11 |
JP2017000141A (en) | 2017-01-05 |
CN102597268B (en) | 2017-09-22 |
BR112012004777A2 (en) | 2019-09-24 |
CN107385034B (en) | 2021-08-17 |
US20110052488A1 (en) | 2011-03-03 |
CN102597268A (en) | 2012-07-18 |
JP2021019594A (en) | 2021-02-18 |
EP2473637A4 (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02485A (en) | ||
PH12018500045A1 (en) | Compositions and methods for treating and diagnosing asthma | |
MX353143B (en) | Biological markers and methods for predicting response to b-cell antagonists. | |
WO2010036960A8 (en) | Methods for treating, diagnosing, and monitoring lupus | |
MY162933A (en) | Chemical compounds | |
WO2013033627A3 (en) | Diagnosis and treatment of arthritis using epigenetics | |
EA201390762A1 (en) | NEW BIOMARKERS TO PREDICT THE OUTCOME OF ANTICATIVE IMMUNOTHERAPY | |
EA201291107A1 (en) | METALLIC ENZYME INHIBITING COMPOUNDS | |
EP2373784A4 (en) | Generation and maintenance of stem cells | |
AU2011260390A8 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
TR201901930T4 (en) | A method for improving microbial activity in soil. | |
EA201491151A1 (en) | METALLIC ENZYME INHIBITING COMPOUNDS | |
EA201390704A1 (en) | METALLIC ENZYME INHIBITING COMPOUNDS | |
MX2010005395A (en) | Method of treating arthritis. | |
MX349011B (en) | Biomarkers for hedgehog inhibitor therapy. | |
WO2011088137A3 (en) | Bad pathway gene signature | |
EP2516624A4 (en) | Cell line 3m | |
MX337203B (en) | Novel jnk inhibitor molecules. | |
IN2012DN00852A (en) | ||
EP2488187A4 (en) | Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same | |
BR112015013771A2 (en) | predictive biomarker of response to treatment of nicotinic acetylcholine alpha 7 receptor activator | |
MX357429B (en) | Predictors for cancer treatment. | |
MX348655B (en) | Biomarkers for predicting sensitivity to cancer treatments. | |
EP3839068A3 (en) | Methods for treating, diagnosing, and monitoring lupus |